Filter By Category
Archives
Share on -
ASUNAPREVIR
Generic Name: ASUNAPREVIR
ABSTRACT -
Asunaprevir is an oral direct-acting antiviral inhibitor of the hepatitis C virus NS3/4A serine protease. It was approved in some countries as part of combination regimens, historically with daclatasvir, for selected HCV genotypes. Current HCV treatment has largely shifted to pan-genotypic regimens, so use depends on local availability, resistance profile, and hepatology guidance.
DOSAGE -
Dosage must follow the local product label if available. It should be used only in combination with appropriate antiviral partners; monotherapy is not appropriate. Baseline genotype, liver function, resistance, and drug interactions guide regimen selection.
SIDE EFFECTS–
Possible or reported side effects may include:
- Fatigue
- Headache
- Nausea
- Diarrhea
- Elevated ALT/AST
- Rash or pruritus
- Anemia if combined with ribavirin-containing regimens
- Hepatic decompensation risk in advanced liver disease
ALLERGIC REACTIONS -
Hypersensitivity may include rash, hives, swelling, dyspnea, or anaphylaxis.
DRUG INTERACTIONS-
Use caution with:
- Strong CYP3A inducers or inhibitors
- Other direct-acting antivirals according to label
- Statins and transporter substrates where relevant
- Ribavirin or interferon when used historically
- Hepatotoxic drugs
- Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, and supplements they are using.
PREAUTIONS–
- Assess HCV genotype, viral load, fibrosis/cirrhosis status, HBV status, liver enzymes, pregnancy status, and concomitant medicines.
- Monitor liver function during therapy.
WARNINGS –
- Not for monotherapy.
- Severe liver injury or allergic reaction requires immediate evaluation.
- Keep out of reach of children.
- In case of overdose, severe reaction, or clinical deterioration, seek immediate medical attention.
Share on -
. Developed by